Current psilocybin trials looking at autism-related depression and anorexia are still in early stages — they're testing whether the treatment is safe and doable, not yet whether it definitively works. Publishing a rigorous 'does it work?' result requires a much stricter study design — with a control group and blinding — that these trials haven't built yet. So before early 2027, expect only safety and 'we could run this study' reports, not definitive proof of effectiveness.
These are open-label pilots. Regulatory-grade efficacy requires blinding these programs haven't built yet.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →